Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Neurology

Does Aicardi-Goutières Syndrome Get Worse Over Time?

At a Glance

Aicardi-Goutières syndrome (AGS) is generally not a continuously degenerative disease. Most children experience an initial "stormy" phase of active brain inflammation and skill loss, followed by a long-term stable phase where disease progression halts and patients can slowly gain new skills.

For most children, the answer is no. Aicardi-Goutières syndrome (AGS) is generally not a continuously degenerative disease. Instead, it typically follows a very specific two-part pattern: a brief, intense period of rapid decline (often called the “stormy” phase), followed by a long-term “stable” phase where the disease stops actively attacking the brain.

The “Stormy” Phase: Initial Inflammation

AGS usually begins with an acute, inflammatory stage known medically as the encephalopathic phase [1][2]. This is often referred to as the “stormy” phase because symptoms appear rapidly and intensely. During this time, the body produces too much type I interferon (a protein normally used to fight viruses), which mistakenly causes severe inflammation in the cerebrospinal fluid and brain [1][3].

The stormy phase most commonly begins in the first few weeks or months of life and can last for several months [1][4]. For parents, this is usually the most frightening time. During this active inflammation, you may notice:

  • The loss of previously learned developmental skills, such as head control or smiling [2]
  • Extreme irritability, unexplained fevers, disrupted sleep, and feeding difficulties—all hallmark behavioral signs of early encephalopathy [1][2]
  • The onset of spasticity (abnormally stiff muscles) or dystonia (involuntary, painful muscle contractions) [5][2]

While watching your child lose skills is terrifying, there is active research into treatments that can be used during the storm. Medications like JAK inhibitors (which help block the immune system’s interferon pathway) are increasingly used to help calm the active inflammation and improve systemic symptoms [6][7].

The “Stable” Phase: A Halt in Progression

Once the initial stormy phase passes and the acute brain inflammation subsides, AGS typically enters a “stable” phase. You will often know the storm is ending when the extreme irritability and continuous crying begin to fade, and your child’s loss of skills finally plateaus.

Unlike progressively degenerative diseases—which continue to get worse over a person’s entire life—AGS is generally considered a static condition once stabilized [8][4]. This means your child will not typically continue losing skills long-term [8].

The brain damage sustained during the stormy phase—such as cerebral atrophy (brain shrinkage) and intracranial calcifications (calcium deposits in the brain)—is generally permanent [1][9]. However, the active destruction largely stops. In fact, rather than continuously declining, many children are able to slowly gain new skills over time with the help of dedicated therapies.

What to Expect Long-Term

Because AGS is genetically diverse, every child’s path is unique [4]. Some children experience severe, neonatal-onset impairment. It is important to know that in the most severe early-onset cases, the extent of the initial brain and organ damage can unfortunately be life-limiting [4]. Conversely, other children have much milder symptoms, preserving average intelligence and independent movement [4][10].

In the stable phase, medical care shifts from fighting acute inflammation to managing lingering symptoms and improving quality of life [4][11]. Long-term care typically involves:

  • Physical, occupational, and speech therapies to maximize movement, communication, and independence
  • Medications or interventions to manage muscle stiffness (spasticity) and involuntary movements (dystonia) [5]
  • Routine monitoring for systemic (body-wide) issues, such as painful skin sores known as chilblains, or hormone imbalances like hypothyroidism and diabetes insipidus [12][13]

While the disease is largely stable, parents should be aware of two exceptions. First, everyday viral illnesses can sometimes trigger temporary disease flare-ups or “mini-storms” where inflammation briefly spikes [14]. Second, some children experience late-onset changes as they grow, which may look like a new stiffening of joints or subtle regressions in motor skills [8].

However, the most important takeaway is that AGS is generally not a continuous downward spiral. Once you make it through the initial storm, the primary focus becomes supporting your child’s stable growth and maximizing their quality of life.

Common questions in this guide

Does Aicardi-Goutières syndrome continuously get worse?
For most children, AGS is not continuously degenerative. It usually features an initial 'stormy' phase of rapid decline followed by a long-term stable phase where active brain damage stops.
What is the stormy phase of AGS?
The stormy phase is an initial period of severe brain inflammation caused by excess type I interferon. During this time, children may experience extreme irritability, fevers, and the loss of previously learned developmental skills.
Are there treatments for the active inflammation in AGS?
Yes, medications like JAK inhibitors are increasingly used during the active inflammatory phase. These drugs help block the immune system's interferon pathway to calm the inflammation and improve systemic symptoms.
Can everyday illnesses cause AGS symptoms to flare up?
Yes, common viral illnesses can sometimes trigger temporary disease flare-ups or 'mini-storms' where inflammation briefly spikes. It is important to have a plan with your doctor to manage viral illnesses and monitor for inflammatory changes.
What does long-term care look like for a child in the stable phase of AGS?
Once the initial stormy phase ends, care shifts to managing lingering symptoms and improving quality of life. This includes physical, occupational, and speech therapies, as well as routine screening for hormone imbalances and skin sores.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How will we monitor if the inflammation is subsiding, and what clinical signs indicate my child is successfully entering the stable phase?
  2. 2.Is my child a candidate for medications like JAK inhibitors to help control the active inflammation during the 'stormy' phase?
  3. 3.Based on my child's specific genetic mutation, what long-term symptoms or hormone imbalances should we actively screen for?
  4. 4.What specialists do we need to add to our care team to support my child's development and comfort during the stable phase?
  5. 5.If my child gets a common viral illness, what steps should we take to prevent or manage a potential inflammatory flare-up?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Efficacy of Baricitinib in the Treatment of Chilblains Associated With Aicardi-Goutières Syndrome, a Type I Interferonopathy.

    Meesilpavikkai K, Dik WA, Schrijver B, et al.

    Arthritis & rheumatology (Hoboken, N.J.) 2019; (71(5)):829-831 doi:10.1002/art.40805.

    PMID: 30666809
  2. 2

    SIGLEC1 (CD169) as a potential diagnostical screening marker for monogenic interferonopathies.

    Orak B, Ngoumou G, Ebstein F, et al.

    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2021; (32(3)):621-625 doi:10.1111/pai.13400.

    PMID: 33099809
  3. 3

    Response to: 'JAK inhibition in STING-associated interferonopathy' by Crow et al.

    Tüngler V, König N, Günther C, et al.

    Annals of the rheumatic diseases 2016; (75(12)):e76 doi:10.1136/annrheumdis-2016-210565.

    PMID: 27811148
  4. 4

    Nucleotide metabolism, leukodystrophies, and CNS pathology.

    Gavazzi F, Gonzalez CD, Arnold K, et al.

    Journal of inherited metabolic disease 2024; (47(5)):860-875 doi:10.1002/jimd.12721.

    PMID: 38421058
  5. 5

    Diagnosis of Aicardi-Goutières Syndrome in Adults: A Case Series.

    Videira G, Malaquias MJ, Laranjinha I, et al.

    Movement disorders clinical practice 2020; (7(3)):303-307 doi:10.1002/mdc3.12903.

    PMID: 32258229
  6. 6

    Exploring emerging JAK inhibitors in the treatment of Aicardi-Goutières syndrome.

    Politano D, Tonduti D, Battini R, et al.

    Expert opinion on emerging drugs 2024; 1-19 doi:10.1080/14728214.2024.2445508.

    PMID: 39704072
  7. 7

    Novel and emerging treatments for Aicardi-Goutières syndrome.

    Tonduti D, Fazzi E, Badolato R, Orcesi S

    Expert review of clinical immunology 2020; (16(2)):189-198 doi:10.1080/1744666X.2019.1707663.

    PMID: 31855085
  8. 8

    Late-Onset Aicardi-Goutières Syndrome: A Characterization of Presenting Clinical Features.

    Piccoli C, Bronner N, Gavazzi F, et al.

    Pediatric neurology 2021; (115()):1-6 doi:10.1016/j.pediatrneurol.2020.10.012.

    PMID: 33307271
  9. 9

    Child Neurology: Aicardi-Goutières Syndrome Presenting as Recurrent Ischemic Stroke.

    Kuang SY, Li Y, Yang SL, Han X

    Neurology 2022; (99(9)):393-398 doi:10.1212/WNL.0000000000200952.

    PMID: 35803721
  10. 10

    Systematic analysis of genotype-phenotype variability in siblings with Aicardi Goutières Syndrome (AGS).

    de Barcelos IP, Woidill S, Gavazzi F, et al.

    Molecular genetics and metabolism 2024; (142(1)):108346 doi:10.1016/j.ymgme.2024.108346.

    PMID: 38368708
  11. 11

    Overlap Diagnostic Odyssey and Full Mouth Rehabilitation of a Juvenile Patient With IFIH1-Related Disorder: A Case of Aicardi-Goutières and Singleton Merten Syndromes Overlap.

    Friedman C, Ari T, Ünsal G, et al.

    Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry 2025; (45(2)):e70026 doi:10.1111/scd.70026.

    PMID: 40197712
  12. 12

    Hepatic Involvement in Aicardi-Goutières Syndrome.

    Gavazzi F, Cross ZM, Woidill S, et al.

    Neuropediatrics 2021; (52(6)):441-447 doi:10.1055/s-0040-1722673.

    PMID: 33445189
  13. 13

    Endocrinopathies in Aicardi Goutières syndrome-A descriptive case series.

    Worth C, Briggs TA, Padidela R, et al.

    Clinical case reports 2020; (8(11)):2181-2185 doi:10.1002/ccr3.3081.

    PMID: 33235754
  14. 14

    Toward a better understanding of type I interferonopathies: a brief summary, update and beyond.

    Yu ZX, Song HM

    World journal of pediatrics : WJP 2020; (16(1)):44-51 doi:10.1007/s12519-019-00273-z.

    PMID: 31377974

This page provides educational information about Aicardi-Goutières syndrome progression. Always consult your child's medical team for specific advice on managing their symptoms and long-term care plan.

Get notified when new evidence is published on Aicardi-Goutières syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.